A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 29 Jan 2018 New source identified and integrated (NCT03410108:ClinicalTrials.gov: US National Institutes of Health).
    • 25 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top